insights_auto
Why is NOV up 3,45%?
Dive Deeperchevron_right
NOV:ETR
Novo Nordisk A/S
€34,19
arrow_upward
+3,45%(+1,14) 1D
7 Okt., 17:35:39 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOV...
Open
€33,28
High
€34,19
Low
€33,12
Mkt. cap
127,45 mjd
Avg. vol.
181,36 k
Volume
169,26 k
52-wk high
€54,87
52-wk low
€30,24
No. of employees
67 k
Open
€33,28
High
€34,19
Low
€33,12
Mkt. cap
127,45 mjd
Avg. vol.
181,36 k
Volume
169,26 k
52-wk high
€54,87
52-wk low
€30,24
No. of employees
67 k
News stories
From web sources and news partners
AD HOC NEWS
·
6 uur gelede
Novo Nordisk stock gains 2.89 percent after-hours to EUR 34.18
Traders Union
·
6 uur gelede
Novo Nordisk shares gain more than 2% after ongoing buyback program and cost-saving measures
Yahoo Finance
·
8 uur gelede
Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
NAI500
·
15 uur gelede
Novo Nordisk Stock Has Fallen Sharply, Does a Long-Term Opportunity Emerge?
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66,7 k
Founded21 Des. 1923
HeadquartersBagsværd, Capital Region of Denmark, Denemarke
SectorPharmaceutical industry
Websitenovonordisk.com